GSK’s COPD Drug Gets A New Name (Breo) But May Face Familiar Challenges At FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The respiratory drug’s fate is uncertain given its mixed Phase III trial results; in two pivotal studies Breo, formerly Relovair, failed to demonstrate superiority to GSK’s Advair.